CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2025 (year ended January 31, 2025). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
570.50MUSDvs all stocks (USD)
Revenue (TTM)
526.47MUSDvs all stocks (USD)
Profit Margin
-69.30%vs Gold peers
Beta
1.32xvs all stocks
52-Week Change
-64.32%vs all stocks
Market Capitalization
570.50MUSDvs all stocks (USD)
Enterprise Value
800.83MUSDvs all stocks (USD)
Price to Sales (TTM)
1.08xvs Gold peers
Price to Book (MRQ)
5.83xvs Gold peers
Enterprise to Revenue
1.52xvs Gold peers
Enterprise to EBITDA
23.98xvs Gold peers
Gross Margin
6.26%vs Gold peers
Profit Margin
-69.30%vs Gold peers
Operating Margin
0.29%vs Gold peers
Return on Assets (TTM)
-10.43%vs Gold peers
Return on Equity (TTM)
-215.82%vs Gold peers
Revenue (TTM)
526.47MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.8660USDUpdated Sep 26, 2026Quarterly Revenue Growth
-18.98%vs Gold peers
Gross Profit (TTM)
-60.08MUSDvs all stocks (USD)
EBITDA (TTM)
49.45MUSDvs all stocks (USD)
Net Income (TTM)
-364.84MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-106.42MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Gold peers
Minority Interest (Equity)
17.13MUSDFY2025 · Jan 31, 2025Revenue
458.88MUSDFY2025 · Jan 31, 2025Cost of Goods Sold
472.19MUSDFY2025 · Jan 31, 2025Gross Profit
-13.32MUSDFY2025 · Jan 31, 2025Operating Income
-55.08MUSDvs all stocks (USD)
Pre-tax Income
-75.52MUSDFY2025 · Jan 31, 2025Income Tax Expense
2.99MUSDFY2025 · Jan 31, 2025Net Income
-78.51MUSDFY2025 · Jan 31, 2025EBIT
-56.59MUSDFY2025 · Jan 31, 2025EBITDA (Income Statement)
49.45MUSDFY2025 · Jan 31, 2025Selling, General & Administrative
38.77MUSDFY2025 · Jan 31, 2025Other Operating Expenses
2.98MUSDFY2025 · Jan 31, 2025Non-operating Interest Income
0.00USDFY2025 · Jan 31, 2025Non-operating Interest Expense
18.93MUSDFY2025 · Jan 31, 2025EPS (Basic)
-0.1600USDFY2025 · Jan 31, 2025EPS (Diluted)
-0.1600USDFY2025 · Jan 31, 2025Basic Shares Outstanding
458.33MSharesFY2025 · Jan 31, 2025Diluted Shares Outstanding
458.33MSharesFY2025 · Jan 31, 2025Net Income from Continuing Operations
-78.51MUSDFY2025 · Jan 31, 2025Minority Interests (P&L)
3.31MUSDFY2025 · Jan 31, 2025Operating Cash Flow
90.12MUSDFY2025 · Jan 31, 2025Free Cash Flow
11.84MUSDFY2025 · Jan 31, 2025Cash & Cash Equivalents (End of Period)
25.95MUSDFY2025 · Jan 31, 2025Income Tax Paid
398.00KUSDFY2025 · Jan 31, 2025Interest Paid
2.23MUSDFY2025 · Jan 31, 2025Starting Profit (CF Statement)
-78.51MUSDFY2025 · Jan 31, 2025Depreciation & Amortization
105.22MUSDFY2025 · Jan 31, 2025Deferred Taxes (CF)
-12.64MUSDFY2025 · Jan 31, 2025Stock-based Compensation
6.33MUSDFY2025 · Jan 31, 2025Other Non-cash Items
10.72MUSDFY2025 · Jan 31, 2025Change in Accounts Receivable (CF)
-5.71MUSDFY2025 · Jan 31, 2025Change in Other Assets/Liabilities
64.71MUSDFY2025 · Jan 31, 2025Capital Expenditures
-78.28MUSDFY2025 · Jan 31, 2025Other Investing Activity
-10.00MUSDFY2025 · Jan 31, 2025Net Investing Cash Flow
-88.28MUSDFY2025 · Jan 31, 2025Long-term Debt Issuance
9.80MUSDFY2025 · Jan 31, 2025Long-term Debt Payments
-44.61MUSDFY2025 · Jan 31, 2025Common Dividends Paid
0.00USDFY2025 · Jan 31, 2025Other Financing Charges
19.30MUSDFY2025 · Jan 31, 2025Net Financing Cash Flow
-4.52MUSDFY2025 · Jan 31, 2025Shares Outstanding
904.55MSharesUpdated Sep 26, 2026Float Shares
865.64MSharesUpdated Sep 26, 2026% Held by Insiders
16.47%vs all stocks
% Held by Institutions
22.14%vs all stocks
Total Cash (MRQ)
61.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0680USDUpdated Sep 26, 2026Total Debt (MRQ)
296.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.92xvs Gold peers
Current Ratio (MRQ)
0.5020xvs Gold peers
Book Value per Share (MRQ)
0.1080USDUpdated Sep 26, 2026Total Assets
721.11MUSDvs all stocks (USD)
Total Current Assets
128.91MUSDFY2025 · Jan 31, 2025Total Liabilities
686.27MUSDFY2025 · Jan 31, 2025Total Non-current Assets
592.20MUSDFY2025 · Jan 31, 2025Total Non-current Liabilities
107.17MUSDFY2025 · Jan 31, 2025Total Current Liabilities
579.09MUSDFY2025 · Jan 31, 2025Cash
25.95MUSDFY2025 · Jan 31, 2025Cash & Cash Equivalents
25.95MUSDFY2025 · Jan 31, 2025Other Short-term Investments
1.43MUSDFY2025 · Jan 31, 2025Accounts Receivable
1.17MUSDFY2025 · Jan 31, 2025Inventory
79.72MUSDFY2025 · Jan 31, 2025Accounts Payable
180.03MUSDFY2025 · Jan 31, 2025Short-term Debt
17.90MUSDFY2025 · Jan 31, 2025Deferred Revenue
246.92MUSDFY2025 · Jan 31, 2025Other Current Liabilities
20.43MUSDFY2025 · Jan 31, 2025Common Stock (Book)
282.92MUSDFY2025 · Jan 31, 2025Retained Earnings
-320.94MUSDFY2025 · Jan 31, 2025Total Shareholders' Equity
34.84MUSDvs all stocks (USD)
52-Week Low
0.4380USDUpdated Sep 26, 202652-Week High
1.85USDUpdated Sep 26, 202652-Week Change
-64.32%vs all stocks
Beta
1.32xvs all stocks
50-Day MA
0.6695USDUpdated Sep 26, 2026200-Day MA
0.8988USDUpdated Sep 26, 2026Avg 10-Day Volume
180.36KSharesUpdated Sep 26, 2026Avg 30-Day Volume
120.55KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.5300USDUpdated Sep 26, 2026Other Income / Expense
-827.00KUSDFY2025 · Jan 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Efficiency from Aging Assets
Revenue per asset reads high, partly because those assets are largely written down.
Reads
Diagnostic
Underinvestment Cash Flow
Less of its cash flow goes to capex than at most of its peers, on an asset base already largely written down.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Depreciation Intensity
Most of its equipment is already written off, and depreciation is larger against its cash flow than its industry's.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Trilogy Metals Inc.
Tier 1ProductionDepleting ExtractiveRiskSenseMaking
PMET Resources Inc.
Tier 1ProductionDepleting ExtractiveRiskSenseMaking
Ramaco Resources Inc.
Tier 1ProductionDepleting ExtractiveFlowRule
Ipek Dogal Enerji Kaynaklari Sanayi ve Ticaret A.S.
Tier 1ProductionDepleting ExtractiveFlowRule
Meridian Mining Plc
Tier 1ProductionDepleting ExtractiveRiskSenseMaking
Thor Explorations Ltd.
Tier 1ProductionDepleting ExtractiveFlowRisk
Gulf Keystone Petroleum Limited
Tier 1ProductionDepleting ExtractiveRuleRisk
Xinjiang Xinxin Mining Industry Co. Ltd.
Tier 1ProductionDepleting ExtractiveFlowRisk
Ipek Doğal Enerji Kaynakları Araştırma ve Üretim A.Ş.
Tier 1ProductionDepleting ExtractiveFlowRisk
IsoEnergy Ltd
Tier 1ProductionDepleting ExtractiveRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Enlivex Therapeutics Ltd.
3 interpretationsUnderinvestment Cash FlowUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Tennant Company
3 interpretationsUnderinvestment Cash FlowEfficiency from Aging AssetsDepreciation Intensity
Travere Therapeutics Inc.
3 interpretationsDepreciation-Heavy Reported ProfitEfficiency from Aging AssetsDepreciation Intensity